Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways

Somatic oncogenic mutations, benign skin lesions and cancer progression: Where to look next?

(2011) Agustí Toll et al.   CELL CYCLE

Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors

(2011) Arkaitz Carracedo et al.   CELL CYCLE

Translational control and cancer therapy

(2011) Konstantinos J. Mavrakis et al.   CELL CYCLE

Metastasis and AKT activation

(2011) Meng Qiao et al.   CELL CYCLE

ERK dimers and scaffold proteins: Unexpected partners for a forgotten (cytoplasmic) task

(2011) Berta Casar et al.   CELL CYCLE

Targeting translation in acute myeloid leukemia: A new paradigm for therapy?

(2011) Jerome Tamburini et al.   CELL CYCLE

Total ERK1/2 activity regulates cell proliferation

(2011) Renaud Lefloch et al.   CELL CYCLE

Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair

(2011) Arun Gupta et al.   CELL CYCLE

PI3K/mTORC1 activation in hamartoma syndromes: Therapeutic prospects

(2011) Vera P. Krymskaya et al.   CELL CYCLE

Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs

(2011) Linda S. Steelman et al.   CELL CYCLE

I B kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia

(2010) N. Chapuis et al.   BLOOD

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation

(2010) A. S. Green et al.   BLOOD

4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors

(2010) Qing-Bai She et al.   CANCER CELL

Antisense HIF-1α prevents acquired tumor resistance to angiostatin gene therapy

(2010) X Sun et al.   CANCER GENE THERAPY

Mammalian Target of Rapamycin Activator RHEB Is Frequently Overexpressed in Human Carcinomas and Is Critical and Sufficient for Skin Epithelial Carcinogenesis

(2010) Z. H. Lu et al.   CANCER RESEARCH

PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling

(2010) E. Halilovic et al.   CANCER RESEARCH

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

(2010) J. R. Dry et al.   CANCER RESEARCH

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Regulation of lymphocyte fate by Ras/ERK signals

(2010) Tomoharu Yasuda et al.   CELL CYCLE

Controlling the cell death mediators Bax and Bak: puzzles and conundrums

(2010) Jamie I. Fletcher et al.   CELL CYCLE

Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells

(2010) John T. Lee et al.   CELL CYCLE

MNK, EIF4E and targeting translation for therapy

(2010) Ricardo L.A. Silva et al.   CELL CYCLE

Targeting prostate cancer based on signal transduction and cell cycle pathways

(2010) John T. Lee et al.   CELL CYCLE

Comparing and contrasting the roles of AMPK and SIRT1 in metabolic tissues

(2010) Marcella Fulco et al.   CELL CYCLE

How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?

(2010) Yohannes Mebratu et al.   CELL CYCLE

Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy

(2010) Stephen L. Abrams et al.   CELL CYCLE

Hot-spot mutations in p110α of phosphatidylinositol 3-kinase (PI3K): Differential interactions with the regulatory subunit p85 and with RAS

(2010) Li Zhao et al.   CELL CYCLE

The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy

(2010) Stephen L. Abrams et al.   CELL CYCLE

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

(2010) N. Chapuis et al.   CLINICAL CANCER RESEARCH

Highly Phosphorylated FOXO3A Is an Adverse Prognostic Factor in Acute Myeloid Leukemia

(2010) S. M. Kornblau et al.   CLINICAL CANCER RESEARCH

Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

(2010) C. A. Pratilas et al.   CLINICAL CANCER RESEARCH

Emerging MEK inhibitors

(2010) James A McCubrey et al.   EXPERT OPINION ON EMERGING DRUGS

Ubiquitination of PTEN (Phosphatase and Tensin Homolog) Inhibits Phosphatase Activity and Is Enhanced by Membrane Targeting and Hyperosmotic Stress

(2010) Helene Maccario et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Shank-interacting protein–like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells

(2010) Lizhi He et al.   JOURNAL OF CLINICAL INVESTIGATION

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

(2010) N Chapuis et al.   LEUKEMIA

Relevant mouse model for human monocytic leukemia through Cre/lox-controlled myeloid-specific deletion of PTEN

(2010) H Yu et al.   LEUKEMIA

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

A coding-independent function of gene and pseudogene mRNAs regulates tumour biology

(2010) Laura Poliseno et al.   NATURE

Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia

(2010) Konstantinos J. Mavrakis et al.   NATURE CELL BIOLOGY

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

(2010) Nallasivam Palanisamy et al.   NATURE MEDICINE

Oncogenic mutations as predictive factors in colorectal cancer

(2010) A Lièvre et al.   ONCOGENE

Drug resistance in mutant FLT3-positive AML

(2010) E Weisberg et al.   ONCOGENE

Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development

(2010) T. Ueda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

(2010) E. W. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies

(2010) I. Astsaturov et al.   Science Signaling

Posttranscriptional Regulation of PTEN Dosage by Noncoding RNAs

(2010) L. He   Science Signaling

Identification of the miR-106b 25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation

(2010) L. Poliseno et al.   Science Signaling

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia

(2009) J. Tamburini et al.   BLOOD

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin

(2009) S. Assouline et al.   BLOOD

Rak Functions as a Tumor Suppressor by Regulating PTEN Protein Stability and Function

(2009) Eun-Kyoung Yim et al.   CANCER CELL

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

(2009) A. Sartore-Bianchi et al.   CANCER RESEARCH

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

(2009) S. Wee et al.   CANCER RESEARCH

Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization

(2009) S. Baritaki et al.   CANCER RESEARCH

Mutations and Response to Epidermal Growth Factor Receptor Inhibitors

(2009) P. Laurent-Puig et al.   CLINICAL CANCER RESEARCH

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

(2009) K. P. Hoeflich et al.   CLINICAL CANCER RESEARCH

Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity

(2009) Juxiang Cao et al.   EMBO JOURNAL

Emerging Raf inhibitors

(2009) James A McCubrey et al.   EXPERT OPINION ON EMERGING DRUGS

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia

(2009) Alberto M Martelli et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics

(2009) Annette S. Gillings et al.   FEBS Journal

Genetic dissection of the miR-17 92 cluster of microRNAs in Myc-induced B-cell lymphomas

(2009) P. Mu et al.   GENES & DEVELOPMENT

miR-19 is a key oncogenic component of mir-17-92

(2009) V. Olive et al.   GENES & DEVELOPMENT

Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and  -secretase inhibitors

(2009) A. Silva et al.   HAEMATOLOGICA

Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody

(2009) N. Chapuis et al.   HAEMATOLOGICA

Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia

(2009) S. Park et al.   HAEMATOLOGICA

X-linked Inhibitor of Apoptosis Protein (XIAP) Regulates PTEN Ubiquitination, Content, and Compartmentalization

(2009) Céline Van Themsche et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Specific Activation of mTORC1 by Rheb G-proteinin VitroInvolves Enhanced Recruitment of Its Substrate Protein

(2009) Tatsuhiro Sato et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway

(2009) S.-Y. Shin et al.   JOURNAL OF CELL SCIENCE

Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

(2009) Pierre Laurent-Puig et al.   JOURNAL OF CLINICAL ONCOLOGY

Bim-targeted cancer therapy: A link between drug action and underlying molecular changes

(2009) T. Akiyama et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction

(2009) S Baritaki et al.   ONCOGENE

Stem Cell Factor SALL4 Represses the Transcriptions of PTEN and SALL1 through an Epigenetic Repressor Complex

(2009) Jiayun Lu et al.   PLoS One

Altering Chemosensitivity by Modulating Translation Elongation

(2009) Francis Robert et al.   PLoS One

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer

(2009) Andrea Sartore-Bianchi et al.   PLoS One

MEK1 mutations confer resistance to MEK and B-RAF inhibition

(2009) C. M. Emery et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

(2009) C. A. Pratilas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activation of the PI3K Pathway in Cancer Through Inhibition of PTEN by Exchange Factor P-REX2a

(2009) B. Fine et al.   SCIENCE

PTEN and the PI3-Kinase Pathway in Cancer

(2008) Nader Chalhoub et al.   Annual Review of Pathology-Mechanisms of Disease

SALL4 is a key regulator of survival and apoptosis in human leukemic cells

(2008) J. Yang et al.   BLOOD

Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α

(2008) Eli R. Zunder et al.   CANCER CELL

Distinct Thresholds Govern Myc's Biological Output In Vivo

(2008) Daniel J. Murphy et al.   CANCER CELL

Effects of lentivirus-mediated HIF-1α knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells

(2008) J Hao et al.   CANCER GENE THERAPY

Phosphatase and Tensin Homologue Deleted on Chromosome 10 Deficiency Accelerates Tumor Induction in a Mouse Model of ErbB-2 Mammary Tumorigenesis

(2008) N. Dourdin et al.   CANCER RESEARCH

The Protein Phosphatase Activity of PTEN Regulates Src Family Kinases and Controls Glioma Migration

(2008) N. Dey et al.   CANCER RESEARCH

Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer

(2008) C. A. Pratilas et al.   CANCER RESEARCH

Novel MEK1 Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung Adenocarcinoma

(2008) J. L. Marks et al.   CANCER RESEARCH

t-Darpp Promotes Cancer Cell Survival by Up-regulation of Bcl2 through Akt-Dependent Mechanism

(2008) A. Belkhiri et al.   CANCER RESEARCH

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

(2008) C. Montagut et al.   CANCER RESEARCH

PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab

(2008) M. Jhawer et al.   CANCER RESEARCH

MicroRNA Expression Profiling in Human Ovarian Cancer: miR-214 Induces Cell Survival and Cisplatin Resistance by Targeting PTEN

(2008) H. Yang et al.   CANCER RESEARCH

Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy

(2008) J. R. Graff et al.   CANCER RESEARCH

Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells

(2008) P. L. Tazzari et al.   CANCER RESEARCH

Tenets of PTEN Tumor Suppression

(2008) Leonardo Salmena et al.   CELL

The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK

(2008) Oliver Rath et al.   CELLULAR SIGNALLING

Tumorigenic activity and therapeutic inhibition of Rheb GTPase

(2008) K. J. Mavrakis et al.   GENES & DEVELOPMENT

Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events

(2008) C. Nardella et al.   GENES & DEVELOPMENT

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability

(2008) Ana Silva et al.   JOURNAL OF CLINICAL INVESTIGATION

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib in advanced hepatocellular carcinoma – We have won a battle not the war

(2008) Peter R. Galle   JOURNAL OF HEPATOLOGY

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy

(2008) J A McCubrey et al.   LEUKEMIA

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

(2008) F Chiarini et al.   LEUKEMIA

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML

(2008) S Park et al.   LEUKEMIA

Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance

(2008) J A McCubrey et al.   LEUKEMIA

Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis

(2008) Bora Gurel et al.   MODERN PATHOLOGY

The Forkhead Transcription Factor FOXO3a Increases Phosphoinositide-3 Kinase/Akt Activity in Drug-Resistant Leukemic Cells through Induction of PIK3CA Expression

(2008) R. C.-Y. Hui et al.   MOLECULAR AND CELLULAR BIOLOGY

Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells

(2008) R. C-Y. Hui et al.   MOLECULAR CANCER THERAPEUTICS

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

(2008) K. S.M. Smalley et al.   MOLECULAR CANCER THERAPEUTICS

Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-Cell Acute Lymphoblastic Leukemia

(2008) F. Fala et al.   MOLECULAR PHARMACOLOGY

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors

(2008) L S Steelman et al.   ONCOGENE

The role of PTEN signaling perturbations in cancer and in targeted therapy

(2008) M Keniry et al.   ONCOGENE

The PTEN–PI3K pathway: of feedbacks and cross-talks

(2008) A Carracedo et al.   ONCOGENE

Post-translational regulation of PTEN

(2008) X Wang et al.   ONCOGENE

A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN

(2008) M. Rahdar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

mTORC1 promotes survival through translational control of Mcl-1

(2008) J. R. Mills et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Helical domain and kinase domain mutations in p110  of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

(2008) L. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MYCN regulates oncogenic MicroRNAs in neuroblastoma

(2007) Johannes H. Schulte et al.   INTERNATIONAL JOURNAL OF CANCER

Bim Expression Is Reduced in Human Cutaneous Melanomas

(2007) Derek L. Dai et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY